Clinical Infectious Diseases · 17 Nov 2026
Trial Endpoints for Aspergillus and Rare Molds: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology
Martin Hoeniglh-index 59, George R Thompsonh-index 20, Jessica S Little, Bart J Rijnders, Ritesh Agarwal, Oliver A Cornely, Jean-Pierre Gangneux, Dimitrios P Kontoyiannis, Cornelia Lass-Flörl, Johan Maertens, Marcio Nucci, Peter G Pappas, Matthew Goon, Emmanuel Roilides, Thomas J Walsh, Carolynn T Jones, Gerald McGwin, Thomas F Patterson, Luis Ostrosky-Zeichner, Monica A Slavinh-index 65
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- Crossref1
- OpenCitations0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Background Invasive mold disease (IMD) remains a substantial cause of patient morbidity and mortality. Aspergillosis and mucormycosis remain the predominant infections encountered, although rare molds continue to emerge as important pathogens. Improvement in patient outcomes has been the result of progress in risk stratification, diagnostics, supportive care, antifungal therapy, and/or prophylaxis, yet substantial challenges remain, requiring the development of novel treatment strategies. Clinical trials evaluating treatment response are currently based on consensus criteria published in 2008. However, advances in clinical mycology and the broadening variety of mold diseases in clinical trials necessitate a revision of these criteria to ensure that adjudication of patient outcomes accurately captures responses to therapeutic intervention. Methods To tackle this task, an international expert panel nominated by the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) was convened. Results The panel produced updated consensus guidance for assessing treatment responses and defining study outcomes in clinical trials of IMD in both adults and children. Conclusions Along with guidance, potential pitfalls in assessing outcome, such as discordant clinical, radiologic, and/or mycologic data and areas for future research are discussed.
What the data shows
- Crossref counts 1 citations, the most of the databases. The others count 0.
- Monica A Slavin has the highest h-index among the authors (65).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (58)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 38 more references
A free account opens the rest of the citing papers and references on every paper’s page.